Medically reviewed by Anita C. Chandrasekaran, MD Hereditary transthyretin (hATTR) amyloidosis is a rare progressive disease that is passed from parent to child. It is caused by a mutant form of ...

About hATTR Amyloidosis Hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) is an inherited, progressively debilitating, and fatal disease caused by variants (i.e., mutations) in the TTR gene.

About hATTR Amyloidosis Hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) is an inherited, progressively debilitating, and fatal disease caused by variants (i.e., mutations) in the TTR gene.

Researchers conducting a large epigenome-wide association study identified several methylation sites associated with hereditary transthyretin amyloidosis (hATTR), a rare, life-threatening disorder ...

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

Sanofi and Alnylam Pharmaceuticals Inc. on Wednesday reported positive results in a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy. Alnylam ...

One step closer to achieving public reimbursement of AMVUTTRA ® for hATTR patients in Canada. MISSISSAUGA, ON, Oct. 18, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that it has signed a ...